Literature DB >> 27468191

Pancreatic cancer stem cell markers and exosomes - the incentive push.

Sarah Heiler1, Zhe Wang1, Margot Zöller1.   

Abstract

Pancreatic cancer (PaCa) has the highest death rate and incidence is increasing. Poor prognosis is due to late diagnosis and early metastatic spread, which is ascribed to a minor population of so called cancer stem cells (CSC) within the mass of the primary tumor. CSC are defined by biological features, which they share with adult stem cells like longevity, rare cell division, the capacity for self renewal, differentiation, drug resistance and the requirement for a niche. CSC can also be identified by sets of markers, which for pancreatic CSC (Pa-CSC) include CD44v6, c-Met, Tspan8, alpha6beta4, CXCR4, CD133, EpCAM and claudin7. The functional relevance of CSC markers is still disputed. We hypothesize that Pa-CSC markers play a decisive role in tumor progression. This is fostered by the location in glycolipid-enriched membrane domains, which function as signaling platform and support connectivity of the individual Pa-CSC markers. Outside-in signaling supports apoptosis resistance, stem cell gene expression and tumor suppressor gene repression as well as miRNA transcription and silencing. Pa-CSC markers also contribute to motility and invasiveness. By ligand binding host cells are triggered towards creating a milieu supporting Pa-CSC maintenance. Furthermore, CSC markers contribute to the generation, loading and delivery of exosomes, whereby CSC gain the capacity for a cell-cell contact independent crosstalk with the host and neighboring non-CSC. This allows Pa-CSC exosomes (TEX) to reprogram neighboring non-CSC towards epithelial mesenchymal transition and to stimulate host cells towards preparing a niche for metastasizing tumor cells. Finally, TEX communicate with the matrix to support tumor cell motility, invasion and homing. We will discuss the possibility that CSC markers are the initial trigger for these processes and what is the special contribution of CSC-TEX.

Entities:  

Keywords:  Cancer stem cells; Crosstalk; Exosomes; Pancreatic cancer; Stem cell markers

Mesh:

Substances:

Year:  2016        PMID: 27468191      PMCID: PMC4948278          DOI: 10.3748/wjg.v22.i26.5971

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  503 in total

1.  Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice.

Authors:  Lei Ding; Zhe Lu; Oded Foreman; Rodney Tatum; Qun Lu; Randall Renegar; Jian Cao; Yan-Hua Chen
Journal:  Gastroenterology       Date:  2011-10-29       Impact factor: 22.682

2.  Protein targeting to exosomes/microvesicles by plasma membrane anchors.

Authors:  Beiyi Shen; Ning Wu; Jr-Ming Yang; Stephen J Gould
Journal:  J Biol Chem       Date:  2011-02-07       Impact factor: 5.157

3.  CD44 regulates pancreatic cancer invasion through MT1-MMP.

Authors:  Wei Jiang; Yaqing Zhang; Kevin T Kane; Meredith A Collins; Diane M Simeone; Marina Pasca di Magliano; Kevin Tri Nguyen
Journal:  Mol Cancer Res       Date:  2015-01-07       Impact factor: 5.852

Review 4.  Early detection and prevention of pancreatic cancer: is it really possible today?

Authors:  Marco Del Chiaro; Ralf Segersvärd; Matthias Lohr; Caroline Verbeke
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

5.  Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells.

Authors:  Haobin Wang; Sanyukta Rana; Nathalia Giese; Markus W Büchler; Margot Zöller
Journal:  Int J Cancer       Date:  2013-02-15       Impact factor: 7.396

6.  Tumor suppressor function of Rab25 in triple-negative breast cancer.

Authors:  Ji-Ming Cheng; Lisa Volk; Deepak Kumar Mummidavarapu Janaki; Sudhir Vyakaranam; Sophia Ran; Krishna A Rao
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

7.  Exosomes in Cancer Disease.

Authors:  Margot Zöller
Journal:  Methods Mol Biol       Date:  2016

8.  Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Authors:  Shalini Makawita; Apostolos Dimitromanolakis; Antoninus Soosaipillai; Ireena Soleas; Alison Chan; Steven Gallinger; Randy S Haun; Ivan M Blasutig; Eleftherios P Diamandis
Journal:  BMC Cancer       Date:  2013-09-03       Impact factor: 4.430

Review 9.  Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets.

Authors:  Christopher S Stipp
Journal:  Expert Rev Mol Med       Date:  2010-01-18       Impact factor: 5.600

10.  Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.

Authors:  M Aga; G L Bentz; S Raffa; M R Torrisi; S Kondo; N Wakisaka; T Yoshizaki; J S Pagano; J Shackelford
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

View more
  28 in total

1.  Assessment of CD133-positive extracellular membrane vesicles in pancreatic cancer ascites and beyond.

Authors:  Christine A Fargeas; Jana Karbanová; Denis Corbeil
Journal:  Med Mol Morphol       Date:  2019-04-05       Impact factor: 2.309

Review 2.  microRNA regulation of human pancreatic cancer stem cells.

Authors:  Yi-Fan Xu; Bethany N Hannafon; Wei-Qun Ding
Journal:  Stem Cell Investig       Date:  2017-01-21

Review 3.  The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers.

Authors:  H Jin; Y Wu; X Tan
Journal:  Clin Transl Oncol       Date:  2017-02-06       Impact factor: 3.405

4.  YOD1 serves as a potential prognostic biomarker for pancreatic cancer.

Authors:  Zhishuo Zhang; Wenxia Zhao; Yiming Li; Yang Li; Hanzeng Cheng; Liyun Zheng; Xiaoyu Sun; Hao Liu; Rongguang Shao
Journal:  Cancer Cell Int       Date:  2022-05-31       Impact factor: 6.429

5.  Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma.

Authors:  Moh'd Khushman; Girijesh Kumar Patel; Javier Ariel Laurini; Arun Bhardwaj; Kelly Roveda; Robert Donnell; Kelley Sherling; Brittany Case; Arthur E Frankel; Sachin Pai; William Taylor; Marcus Chuan Beng Tan; Meir Mizrahi; Cindy Nelson; Mary Wyatt; Mary Patton; Steven McClellan; Seema Singh; Bin Wang; Ajay P Singh
Journal:  J Gastrointest Oncol       Date:  2019-08

Review 6.  Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

Review 7.  Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications.

Authors:  Jiangdong Qiu; Gang Yang; Mengyu Feng; Suli Zheng; Zhe Cao; Lei You; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  Mol Cancer       Date:  2018-01-05       Impact factor: 27.401

8.  Proteins and Molecular Pathways Relevant for the Malignant Properties of Tumor-Initiating Pancreatic Cancer Cells.

Authors:  Lisa Samonig; Andrea Loipetzberger; Constantin Blöchl; Marc Rurik; Oliver Kohlbacher; Fritz Aberger; Christian G Huber
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

Review 9.  CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression.

Authors:  Zhe Wang; Kun Zhao; Thilo Hackert; Margot Zöller
Journal:  Front Cell Dev Biol       Date:  2018-08-28

Review 10.  The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.

Authors:  Shun Wang; Yan Zheng; Feng Yang; Le Zhu; Xiao-Qiang Zhu; Zhe-Fang Wang; Xiao-Lin Wu; Cheng-Hui Zhou; Jia-Yan Yan; Bei-Yuan Hu; Bo Kong; De-Liang Fu; Christiane Bruns; Yue Zhao; Lun-Xiu Qin; Qiong-Zhu Dong
Journal:  Signal Transduct Target Ther       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.